Ponatinix 45 Ponatinib hydrochloride

Product Name: Ponatinib

Specification: 45 mg × 30 tablets

Manufacturer: Beacon Pharmaceutical

Ponatinib is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI). On December 14, 2012, Ponatinib was granted accelerated approval by the U.S. FDA for marketing and sale. It is indicated for the treatment of chronic myeloid leukemia (CML) with the ABL T315I mutation, or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); it may also be used to treat CML or ALL in patients who are resistant to or intolerant of previous tyrosine kinase inhibitors (TKIs).

Although first- and second-generation TKIs have improved clinical outcomes for patients with CML and Ph+ ALL, drug resistance still occurs in some patients with BCR-ABL mutations—particularly the T315I mutation. Prior to the approval of the third-generation TKI, Ponatinib, no TKIs on the market were capable of overcoming the resistance, refractoriness, or intolerance observed in these patients with BCR-ABL mutations. Among patients with accelerated-phase CML, blast-phase CML, and Ph+ ALL, Ponatinib achieved major hematologic response rates of 55%, 31%, and 41%, respectively. Consequently, Ponatinib stands as a potent oral TKI and represents a critically important clinical option for patients with refractory CML—especially those harboring the T315I mutation.

In a post-hoc, retrospective, indirect comparison of overall survival (OS)—conducted between patients receiving Ponatinib monotherapy in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial and patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) as reported by the European Group for Blood and Marrow Transplantation (EBMT) Registry—CML patients were stratified by disease phase, and Ph+ ALL patients were analyzed separately. Kaplan-Meier survival curves and multivariate Cox proportional hazards models were employed to compare OS between the intervention groups, with adjustments made for time from diagnosis to intervention, age, gender, and geographic region; OS rates at 24 and 48 months, as well as median OS, were reported.

Patients taking Ponatinib should be monitored closely for congestive heart failure, hypertension, pancreatitis, hemorrhage, and cardiac arrhythmias, as well as for various other physiological parameters. Congestive Heart Failure: Monitor patients for signs and symptoms of congestive heart failure and treat as clinically indicated. Hypertension: Monitor for hypertension and treat as clinically indicated. Pancreatitis: Monitor serum lipase levels monthly; interrupt or discontinue Ponatinib. Hemorrhage: Interrupt Ponatinib in cases of severe hemorrhage. Fluid Retention: Monitor patients for fluid retention; interrupt or discontinue Ponatinib.

Ponatinix, manufactured by Beacon Pharmaceuticals, is the world's first generic version of Ponatinib and remains, to date, the only generic version legally approved for production by government regulatory authorities.

Backed by investment from a European consortium, Beacon Pharmaceuticals is the only major pharmaceutical enterprise in South Asia that adheres to EU technical standards and is listed on the main boards of Bangladesh's two major stock exchanges; its products comply with both European Pharmacopoeia and United States Pharmacopoeia standards.

Compared to other so-called generic equivalents from unverified sources—even if their active ingredient content appears similar to Beacon's products—they often lack strictly regulated GMP-compliant manufacturing facilities and rigorous government oversight. Consequently, their dissolution rates and bioavailability—factors critical to drug absorption—differ significantly from those of Beacon's products. To ensure patient safety, please exercise caution when making your selection.

Indications: Indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase Chronic Myeloid Leukemia (CML) who are resistant to or intolerant of prior tyrosine kinase inhibitor therapy.

Dosage and Administration:

The recommended dose is 45 mg, taken orally once daily, with or without food.

Treatment should be continued as long as there is no evidence of disease progression or unacceptable toxicity.

Adjust dosage or interrupt administration in cases of hematologic or non-hematologic toxicity.

Common Adverse Reactions:

The most common non-hematologic adverse reactions (≥20%) are hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions include thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia. Use in Specific Populations:

Congestive Heart Failure: Monitor patients for signs and symptoms of congestive heart failure and treat as clinically indicated.

Hypertension: Monitor for hypertension and treat as clinically indicated.

Pancreatitis: Monitor serum lipase levels monthly; interrupt or discontinue treatment.

Hemorrhage: Interrupt treatment in cases of severe hemorrhage.

Fluid Retention: Monitor patients for fluid retention; interrupt, reduce the dose, or discontinue treatment as appropriate.

Arrhythmias: Monitor for symptoms of arrhythmias.

Myelosuppression: Thrombocytopenia, neutropenia, and anemia may require dose interruption or reduction. Monitor complete blood counts every two weeks for the first 3 months, then monthly, and as clinically indicated. Interrupt treatment for ANC < 1000/mm³ or platelet counts < 50,000/mm³. Tumor Lysis Syndrome: Ensure adequate hydration and correct elevated uric acid levels prior to initiating treatment with Ponatinib.

Impaired Wound Healing and Gastrointestinal Perforation: Temporarily interrupt treatment in patients undergoing major surgical procedures.

Embryo-Fetal Toxicity: May cause fetal harm. Advise women of the potential risk to the fetus.

Product Specifications

Product Name: Ponatinib 45mg × 30 Tablets (Beacon Ponatinix 45)

Common Name: Ponatinib

Active Ingredient: Ponatinib

Dosage Form: Tablets

Specification: 45mg × 30 tablets/box

Manufacturer: Beacon Pharmaceutical

Indications: Indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to or intolerant of prior tyrosine kinase inhibitor therapy.

Dosage and Administration: The recommended dose is 45 mg taken orally once daily, with or without food;

Treatment should be continued as long as there is no evidence of disease progression or unacceptable toxicity;

Adjust dosage or interrupt administration for hematologic and non-hematologic toxicities.